Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 3/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977701 | 0.94 | KLK7 (0.34) | BCHEACHETLR2P2RY12PPARG | |
| SCHEMBL30977728 | 0.91 | BCHE (0.32) | BCHEACHE | |
| SCHEMBL30977717 | 0.90 | KLK7 (0.37) | BCHEACHETLR2PPARGTDP1 | |
| SCHEMBL30977707 | 0.90 | KLK7 (0.37) | BCHEACHETLR2PPARGTDP1 | |
| SCHEMBL31035789 | 0.89 | TLR2 (0.38) | TLR2 | |
| SCHEMBL30977742 | 0.89 | KLK7 (0.36) | BCHETLR2PPARGTDP1 | |
| SCHEMBL30977769 | 0.88 | KLK7 (0.33) | BCHEACHETLR2TDP1 | |
| SCHEMBL30977768 | 0.88 | CHRM2 (0.32) | BCHEACHEP2RY12PPARG | |
| SCHEMBL30977733 | 0.87 | TLR2 (0.37) | TLR2 | |
| SCHEMBL30977766 | 0.86 | CTSK (0.33) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638417-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | Nanovation Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | disclosed |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-12-05 | — | — | US | disclosed |
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | NANOVATION THERAPEUTICS INC. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-08-08 | — | — | US | disclosed |
| WO-2024130421-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | SLC43A1, NSUN3, NSUN2 | BCHE 3833/4885ACHE 4820/4885TLR2 3615/4885 |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | BCHE 3833/4885ACHE 4820/4885TLR2 3615/4885 |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | BCHE 3833/4885ACHE 4820/4885TLR2 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.